Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01092325 · ClinicalTrials.gov registry record · Phase 1
Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01092325 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 28 participants.
The verdict
NCT01092325, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
A Phase 1-2a Study of CXL-1020-01 in Patients with Stable Heart Failure
Interventions
- DRUG CXL-1020
- DRUG Placebo for CXL-1020 Cohort 1
- DRUG Placebo for CXL-1020 Cohort 2
- DRUG CXL-1020 Dose for Echo Cohort A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01092325
The ClinicalTrials.gov registry entry for NCT01092325 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which CXL-1020 is the first listed.
NCT01092325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01092325 about?
NCT01092325 is a clinical study titled "Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure". A Phase 1-2a Study of CXL-1020-01 in Patients with Stable Heart Failure
What is the current status of trial NCT01092325?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2009-06. Estimated completion is 2010-05.
What interventions are being tested in trial NCT01092325?
The interventions under investigation include: CXL-1020 (DRUG), Placebo for CXL-1020 Cohort 1 (DRUG), Placebo for CXL-1020 Cohort 2 (DRUG), CXL-1020 Dose for Echo Cohort A (DRUG).
Who is sponsoring clinical trial NCT01092325?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.